Skip to main content
. 2014 Mar 10;9(3):e90909. doi: 10.1371/journal.pone.0090909

Table 4. Sorafenib dose modifications.

Dose modification BCLC stage B (N = 11) BCLC stage C (N = 17) Overall (N = 28)
Dose delay, N (%) 6 (55) 10 (59) 16 (57)
Dose further delay, N (%) 0 1 (6) 1 (4)
Dose reduction, N (%) 7 (64) 4 (24) 11 (39)
Dose resumed to starting dose, N (%) 1 (9) 2 (12) 3 (11)
Dose permanently discontinued following modification, N (%) 0 1 (6) 1 (4)